Researchers developed a new algorithm that can use a single OCT scan to predict whether a patient with diabetic macular edema is likely to respond to anti-VEGF treatments. They tested it on pretreatment OCT images (top row) and used post-treatment OCT images (bottom row) to track response to treatment. Case 24 and 36 responded to treatment.
Credit: Sina Farsiu, Duke University
New algorithm poised to help doctors individualize treatment for diabetic macular edema
A new approach that uses artificial intelligence to analyze retinal images could one day help doctors select the best treatment for patients with vision loss from diabetic macular edema. This diabetes complication is a major cause of vision loss among working-age adults.
Anti-vascular endothelial growth factor (VEGF) agents are widely used as the first line of therapy for diabetic macular edema, but they don’t work for everyone. There’s a need to identify who would benefit from the therapy because it requires multiple injections that are costly and burdensome for both patients and physicians.
“We developed an algorithm that can be used to automatically analyze optical coherence tomography (OCT) images of the retina to predict whether a patient is likely to respond to anti-VEGF treatments,” said research team leader Sina Farsiu from Duke University. “This research represents a step toward precision medicine, in which such predictions help clinicians better select first-line therapies for patients based on specific disease conditions.”
In The Optical Society (OSA) journal Biomedical Optics Express, Farsiu and colleagues show that the new algorithm can analyze just one pre-treatment volumetric scan to accurately predict whether a patient is likely to respond to anti-VEGF therapy.
“Our approach could potentially be used in eye clinics to prevent unnecessary and costly trial-and-error treatments and thus alleviate a substantial treatment burden for patients,” Farsiu said. “The algorithm could also be adapted to predict therapy response for many other eye diseases, including neovascular age-related macular degeneration.”
Predicting treatment response
The algorithm developed by the researchers is based on a novel convolutional neural network (CNN) architecture, a type of artificial intelligence that can analyze images by assigning importance to various aspects or objects. They used the algorithm to examine images acquired with OCT, a noninvasive technology that produces high-resolution cross-sectional retinal images and is the standard of care for assessing and treating many eye conditions.
“Unlike previously developed approaches, our algorithm requires OCT images from only a single pretreatment timepoint,” said Reza Rasti, first author of the paper and a postdoctoral scholar in Farsiu’s laboratory. “There’s no need for time-series OCT images, patient records or other metadata to predict therapy response.”
The new algorithm preserves and highlights global structures in the OCT image while enhancing local features from diseased regions to efficiently use retinal thickness information. To help with treatment decision making, the researchers incorporated an additional step that looks for CNN-encoded features that are highly correlated with anti-VEGF response.
Testing the algorithm
The researchers tested their new algorithm with OCT images from 127 patients who had been treated for diabetic macular edema with three consecutive injections of anti-VEGF agents. They applied the algorithm to analyze OCT images taken before the anti-VEGF injections, then compared the algorithm’s predictions to OCT images taken after anti-VEGF therapy to confirm whether the therapy improved the condition.
Based on the results, the researchers calculated that the algorithm would have an 87 percent chance of correctly predicting who would respond to treatment. It exhibited an average precision and specificity of 85 percent and a sensitivity of 80 percent.
Next, the researchers plan to confirm and extend the findings from this pilot study by performing a larger observational trial of patients who have not yet undergone treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Diabetic macular edema
- Choriocapillaris flow deficit may predict risk of retinopathy and macular edema in diabetics
Choriocapillaris flow deficit may predict risk of retinopathy and macular edema in diabetics suggests a recent study published in the American Journal of OphthalmologyA study was conducted ...
- Diabetic Macular Edema Treatment Global Market Report 2022: Intravitreal Implants Set to Take Center Stage
The "Diabetic Macular Edema Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been ...
- 4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs
Expands Large Market Pulmonology Portfolio Following Positive Clinical Data in Cystic Fibrosis to Include Alpha-1 Antitrypsin Deficiency Preclinical Program Reports Program Updates and Interim ...
- Macular Degeneration (AMD) and Other Retinal Diseases Drugs market is projected to grow at a CAGR of 10.74% by 2032: Visiongain Reports Ltd
Visiongain has published a new report entitled Macular Degeneration (AMD) and Other Retinal Diseases Drugs 2022-2032. It includes profiles of Macular Degeneration (AMD) and Other Retinal Diseases ...
- Stuart Therapeutics, Inc. announces, expansion of its development pipeline, additions to its Scientific Advisory Board
Stuart Therapeutics, Inc. announces that it has expanded its drug development pipeline, adding programs in diabetic macular edema and myopia. The company has completed initial pre-clinical studies ...
Go deeper with Google Headlines on:
Diabetic macular edema
[google_news title=”” keyword=”diabetic macular edema” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Diabetes related vision loss
- Study reveals obesity-related trigger that can lead to diabetes
Researchers at Washington University School of Medicine in St. Louis have found that a defect in an enzyme called APT1 interferes with the ability to secrete insulin, contributing to the development ...
- Age-Related Eye Disease Tied to Increased COVID-19 Risk
Age-related macular degeneration (AMD), linked to vision loss, significantly increases the risk of severe COVID-19. Scientists are exploring why.
- Watch for Type 2 Diabetes Symptoms as New Study Predicts "Startling Rise"
Diet plays a major role with diabetes and poor food choices increase the risk and complications for anyone with the disease.
- Type 2 diabetes in young people puts their eyes at risk
Sixteen-year-old Karl is seen for the first time in my optometry practice. He was referred to me for a fluctuating vision problem. During his examination, I saw signs suggesting he may have diabetes, ...
- 'I Took Diabetes Drug Qsymia for Weight Loss & Went Blind—Here's How I Recovered'
RELATED: "Weight Loss" Drug Meant for Diabetes Now Facing Shortages ... (For context, Brown's normal vision is 20/10 when wearing glasses.) She was understandably scared and knew vision issues ...
Go deeper with Google Headlines on:
Diabetes related vision loss
[google_news title=”” keyword=”diabetes related vision loss” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]